Helicore Biopharma has announced its emergence from stealth mode with $65 million in Series A financing, co-led by founding investor Versant Ventures and by OrbiMed. 

The company is focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions. 

Helicore’s most advanced asset, HCR-188, is a clinical stage monoclonal antibody (mAb) designed to bind GIP. The company’s portfolio includes GIP antibody conjugates, including GLP-1 and other combinations, designed to address specific obesity subpopulations. 

“Recent scientific advances have fundamentally changed our understanding of obesity and the conditions associated with it,” said Gerrit Klaerner, President and CEO of Helicore. “Current treatments, though impactful, often fall short of addressing the complex, long-term needs of patients. By targeting GIP directly, we’ve rapidly advanced a differentiated portfolio that may deliver superior treatment outcomes through enhanced efficacy, tolerability, and convenient dosing regimens.” 

Individuals carrying genetic loss-of-function mutations in either GIP or GIPR are protected from obesity and exhibit lean phenotypes thought to arise from diminished GIP/GIPR-mediated triglyceride uptake in adipocytes.  

Preclinical studies of HCR-188 in combination with GLP-1 suggest preferential loss of fat over lean mass, potentially enabling a higher quality of weight loss than can be achieved with GLP-1 alone. 

Furthermore, unlike receptor-focused GIPR antagonists, HCR-188 binds circulating GIP ligand, which is expressed exclusively by K cells in the small intestine. In contrast, GIPR is expressed throughout the body, including in fat and in deep brain structures.  

By antagonising GIP in the periphery and blocking transit to the central nervous system, Helicore says it’s compounds may uniquely prevent GIP signalling in the brain, potentially restoring leptin sensitivity that may support increased satiety as well as reduced consumption and fat deposition.

Diana Spencer, Senior Digital Content Editor, DDW